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ABSTRACT: The aim of this study was to investi-
gate the association between drug exposure and disease
severity in SCA types 1, 2, 3 and 6. The Clinical Research
Consortium for Spinocerebellar Ataxias (CRC-SCA)
enrolled 319 participants with SCA1, 2, 3, and 6 from 12
medical centers in the United States and repeatedly
measured clinical severity by the Scale for Assessment
and Rating of Ataxia (SARA), the Unified Huntington’s
Disease Rating Scale part IV (UHDRS-IV), and the 9-item
Patient Health Questionnaire during July 2009 to May
2012. We employed generalized estimating equations in
regression models to study the longitudinal effects of
coenzyme Q10 (CoQ10), statin, and vitamin E on clinical
severity of ataxia after adjusting for age, sex, and patho-
logical CAG repeat number. Cross-sectionally, exposure
to CoQ10 was associated with lower SARA and higher
UHDRS-IV scores in SCA1 and 3. No association was
found between statins, vitamin E, and clinical outcome.
Longitudinally, CoQ10, statins, and vitamin E did not
change the rates of clinical deterioration indexed by
SARA and UHDRS-IV scores within 2 years. CoQ10 is
associated with better clinical outcome in SCA1 and 3.
These drug exposures did not appear to influence clinical
progression within 2 years. Further studies are warranted
to confirm the association. VC 2014 International Parkinson
and Movement Disorder Society
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Spinocerebellar ataxias (SCAs) are a group of
autosomal-dominant cerebellar degenerative disorders,
characterized by gait difficulty, speech disturbance, and
loss of hand dexterity. SCA1, 2, 3, and 6 are the most
common types of SCAs1; their respective pathological
CAG repeat expansions in ATXN1, 2, 3, and CAC-
NA1A genes cause abnormal polyglutamine protein
inclusions and neurodegeneration.1 SCAs are rare dis-
eases with a prevalence of 3 per 100,000.1 To study
these rare disorders, ataxia specialists from 12 medical
centers in the United States organized Clinical Research
Consortium for Spinocerebellar Ataxias (CRC-SCAs) and
prospectively followed up SCA1, 2, 3, and 6 patients. A
similar consortium in Europe, EUROSCA, was also
established to study the natural history of SCAs.2 The
Scale for Assessment and Rating of Ataxia (SARA) was
chosen to measure disease progression in SCAs.3,4
Despite the lack of evidence-based treatment, several
mechanism-based therapeutic approaches have been
proposed and employed in clinical practice. Polyglut-
amine repeats can directly activate the mitochondrial
apoptotic pathway leading to neuronal death.5-8 Coen-
zyme Q10 (CoQ10) is a key mitochondrial respiratory
chain cofactor, and primary CoQ10 deficiency can
cause cerebellar ataxia,9 which is well responsive to
CoQ10 supplement.10 Therefore, CoQ10 could be a
potential candidate for treating SCAs.11,12 Statins are
a class of cholesterol-lowering medications that have
effects on lipid metabolism, cell signaling, and anti-
inflammation.13 Statin use has been shown to reduce
the incidence of Alzheimer’s disease (AD),14 and dis-
continuation of statin is associated with increased inci-
dence of Parkinson’s disease.15 Disrupted cholesterol
hemostasis has been discovered in polyglutamine dis-
orders, such as Huntington’s disease.16 Whether sta-
tins are also beneficial in other neurodegenerative
diseases, such as SCAs, is not clear. Vitamin E is a
potent antioxidant and has a potential effect of disease
modification in AD animal models.17 Ataxia is also a
prominent symptom in vitamin E deficiency and abeta-
lipoproteinemia.18 It remains unknown whether vita-
min E would have similar beneficial effects in other
cerebellar ataxias. Varenicline and riluzole have been
found to improve ataxia symptoms within a short-term
treatment period,19,20 and whether these short-term
benefits will continue requires longer observation.
There are very few medications such as varenicline
being tested specifically for SCAs.19 Development of
drugs for SCAs was mainly hindered by disease rarity
and the need for long-term follow-ups. Therefore, we
repeatedly measured SARA scores, the Unified Hun-
tington’s Disease Rating Scale part IV (UHDRS-IV)
and depressive symptoms (the 9-item Patient Health
Questionnaire; PHQ-9) to study the longitudinal
effects of candidate drugs, including CoQ10, statins




Study participants were recruited by ataxia or move-
ment disorders specialists during July 2009 to May
2012 from 12 CRC-SCA centers at Columbia Univer-
sity, Emory University, Massachusetts General Hospi-
tal, Johns Hopkins University, University of California
Los Angeles, University of California San Francisco,
University of Chicago, University of Florida, Univer-
sity of Michigan, University of Minnesota, University
of South Florida, and University of Utah. These
patients were referred to specialty clinics by patients
themselves, community physicians, local support
groups, and the National Ataxia Foundation. The uni-
form study protocol was approved by the local institu-
tional review boards and the informed consents were
obtained from all participants. Our inclusion criteria
were (1) the presence of ataxia, (2) definite genetic
diagnosis of SCA1, 2, 3, or 6 either for the subject or
another affected family member with ataxia, (3) will-
ingness of participation, and (4) age of 6 years and
older. Exclusion criteria were (1) known recessive,
X-linked, and mitochondrial ataxias, (2) exclusion of
SCA1, 2, 3, and 6 by previous genetic tests, and (3)
concomitant disorder(s) that affect SARA and other
ataxia measurements used in this study. Basic demo-
graphics were recorded, and all participants were
asked to provide blood samples for SCA genotyping.
Study participants were followed every 6 months until
2 years from the baseline visit or the end of August
2012 when the study was closed. In each visit, the
severity of ataxia was recorded by a trained ataxia
expert using SARA scores. We also used the UHDRS-
IV to assess the functional impairment and PHQ-9 to
evaluate depression, which is a common comorbidity
in SCA patients.21 Information on concurrent medica-
tion was also collected.
Genetic Testing
DNA samples from blood of 263 participants were
obtained, and CAG repeat expansions were deter-
mined in Dr. Stefan Pulst’s laboratory. The Qiagen
FlexiGene DNA Kit (Qiagen, Hilden, Germany) was
used to extract DNA and CAG repeat expansions of
SCAs were determined by multiplex polymerase chain
reaction, followed by capillary electrophoresis with
internal standards. Regenotyping and Sanger sequenc-
ing were performed for verification of repeat length in
10% of all samples. For 38 patients whose blood sam-
ples were not available in the research lab, we used
the repeat numbers from the commercial labs.
Predictor Variables
Concomitant use of CoQ10, statins, vitamin E, rilu-
zole, or varenicline at baseline is our major predictor
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and was treated as a dichotomous variable. We further
divided statins into lipophilic (simvastatin, lovastatin,
fluvastatin, and atorvastatin) and lipophobic statins
(pravastatins and rosuvastatin).22 Statin could poten-
tially lower the levels of CoQ10,23 and the interaction
term (statin 3 CoQ10) was thus entered for secondary
analysis. Although the duration and dosage of medica-
tion exposure were not consistently available, we fur-
ther tested the effect of dose dependency in secondary
analysis to confirm the primary outcome.
Outcome Variables
SARA is our primary outcome, which measures
motor performance with a total score ranging from 0
to 40. Higher SARA scores reflected poor motor per-
formance. There were 25 questions regarding func-
tional performance in daily activities in the UHDRS-
IV. One point was given if the answer to the individ-
ual question was positive; the total score of UHDRS-
IV ranged from 0 to 25, and higher scores indicated
better functional status. The PHQ-9 used nine ques-
tions to assess depressive mood over the past 2 weeks.
Four levels were rated (not at all50; several days5 1;
more than half the days5 2; nearly every day53) in
each question, and higher scores (range, 0-27) reflected
the severity of depression. The above outcome measures
were all treated as continuous variables.
Statistical Analysis
Participants with repeated outcome measures were
entered into analyses. SCA1, 2, 3, and 6 were treated
as four independent cohorts and analyzed separately.
We employed repeated-measures linear regression (an
exchangeable working within-subject correlation
model by a generalized estimating equation [GEE]) to
compute average rates of disease progression in each
SCA group and assess the associations between certain
drug exposures and disease severity after controlling
for age, sex, and pathological CAG repeat number.
CAG repeat expansions have been shown to be
strongly correlated with age of ataxia onset, explain-
ing 55% to 70% of the variability24,25; thus, we did
not include both age of onset and CAG repeat expan-
sions in our primary analysis. Age of ataxia onset or
disease duration was additionally included in the mod-
els in the secondary analysis. The longitudinal effects
of drug exposure on disease progression during the
2-year observation period were assessed by entering
the interaction terms (drug 3 time) into the GEE
models. Coefficients of the interaction terms reflected
the direction and magnitude of how certain drug
exposures modified the disease course in SCAs.
All statistical analyses and graphics were performed
in the software R (version 2.11.1; R Foundation for
Statistical Computing, Vienna, Austria). All tests of
statistical significance were conducted at the two-
tailed a level of 0.05. Bonferroni’s correction was
made to account for multiple comparisons for five dif-
ferent drugs and was applied consistently to the
reported analyses. The two-tailed a level of individual
test was 0.01.
Results
Baseline Features and Disease Progression
A total of 319 patients in the CRC-SCA cohort
were followed up with repeated measures of SARA
scores and other health outcome indicators (Table 1).
SCA3 was the most common type of SCA in the
cohort (40.4%). Mean age at enrollment was around
15 years older for the SCA6 than SCA1, 2, and 3.
After taking age and sex into account, baseline SARA
score was higher in the SCA2 group (P5 0.02),
whereas other outcome indicators, including UHDRS-
IV and PHQ-9, did not differ across SCA groups.
Clinical progression of SCAs in 2 years is well cap-
tured by SARA scores and UHDRS-IV scores in the
CRC-SCA cohort.26 Older age and greater number of
CAG repeats were associated with higher SARA
scores, but not faster progression. The rate of clinical
progression is similar to the EUROSCA cohort.2
CoQ10 and SARA Scores
CoQ10 was given to nearly one quarter of patients
in this cohort (23.3%), more often than statins
(13.2%), vitamin E (12.6%), riluzole (4.7%), and var-
enicline (2.2%). The median daily dosage of CoQ10
exposure was 600 mg (n568; range, 100-2,400), and
the mean duration of CoQ10 exposure before study
visits was 34.7 months (n533; range, 1-139). Cross-
sectionally, CoQ10 use was significantly associated
with lower baseline SARA scores or better outcome in
SCA1 and 3 (CoQ10 exposure vs. no CoQ10 expo-
sure, or CoQ10 coefficient, SCA1: b525.90,
P5 0.008; SCA2: b523.20, P5 0.11; SCA3:
b525.54, P< 0.001; SCA6: b521.17, P5 0.54),
and the effects remained significant with an additional
adjustment for age of ataxia onset (SCA1: b525.67,
P< 0.001; SCA2: b521.55, P5 0.43; SCA3:
b524.95, P< 0.001; SCA6: b521.04, P50.57) or
disease duration (SCA1: b525.87, P50.01; SCA2:
b521.44, P5 0.55; SCA3: b524.35, P50.002;
SCA6: b521.38, P5 0.41). With daily dosage of
CoQ10 as our predictor, SCA patients who took
higher daily dose of CoQ10 would have lower base-
line SARA scores or better outcome by a 4.52-point
difference (95% confidence interval: 26.84, 22.20)
for every 1,000-mg increase in daily CoQ10 exposure,
after adjusting for age, sex, and CAG repeat number.
The relationship between CoQ10 dosage and baseline
SARA scores is shown in the box plot (Fig. 1). The
main effect was driven by the SCA3 group (26.07;
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P5 0.003), though all other groups were in the same
direction (SCA1: 25.4, P5 0.13; SCA2: 25.55,
P5 0.14; SCA6: 22.36, P5 0.13). Longitudinally,
CoQ10 exposure did not modify the annual rates of
change in SARA scores across all SCA groups (CoQ10
exposure and time interaction coefficient; SCA1:
b520.05, P50.43; SCA2: b520.06, P5 0.28;
SCA3: b520.01, P50.76; SCA6: b520.05, P5
0.41; Table 2). Only 4 patients discontinued CoQ10
during the 2-year follow-ups, and 1 began taking
CoQ10 during the study. Given that the discontinua-
tion frequency was low, we treated CoQ10 use as a
time-independent variable based on baseline informa-
tion. We performed a sensitivity analysis by recoding
these 4 patients as CoQ10 nonusers and still obtained
similar results.
Statins, Vitamin E, and SARA Scores
Cross-sectionally, statin exposure and baseline SARA
scores in SCA1, 2, and 3 were not related, but statin
use was associated with worse baseline SARA scores in
the SCA6 group (statin exposure vs. no statin exposure,
or statin coefficient; SCA1: b521.29, P5 0.66; SCA2:
b521.08, P50.58; SCA3: b521.26, P5 0.83;
SCA6: b54.50, P5 0.02); the negative association dis-
appeared after Bonferroni’s correction and remained
similar when we also adjusted for age of ataxia onset
(SCA6: b5 4.52, P50.006) or disease duration
(SCA6: b5 4.55, P5 0.02) or after excluding lipopho-
bic statins (SCA6: b5 5.05, P50.018). Longitudinally,
statins did not modify the 2-year clinical course meas-
ured by SARA scores either (statin exposure and time
interaction coefficient; SCA1: b5 0.05, P50.52;
SCA2: b520.09, P5 0.19; SCA3: b520.07, P5
0.08; SCA6: b5 0.05, P50.47). Vitamin E was associ-
ated with neither baseline SARA scores nor the progres-
sion of SARA scores over time in all SCAs (Table 2).
CoQ10, Statins, Vitamin E, and UHDRS-IV
CoQ10 use was also significantly associated with
higher baseline UHDRS-IV scores (mean difference: 3.2
points) or better outcomes in SCA1 and 3 (CoQ10
exposure vs. CoQ10 exposure, or CoQ10 coefficient;
SCA1: b5 4.85, P< 0.001; SCA2: b52.59, P5 0.04;
SCA3: b5 3.65, P< 0.001; SCA6: b51.87, P5 0.14).
Statins and vitamin E were not associated with
UHDRS-IV scores in all SCAs (Table 3). The total
number of patients with riluzole or varenicline expo-
sure was too small (riluzole, n515; varenicline, n5 7)
to meaningfully assess the drug effects. Age of onset,
CAG repeat number, and other demographic features
were mostly comparable between CoQ10 users and
nonusers (Table 4), except for the disease duration,
which seemed to be longer in non-CoQ10 users than in
CoQ10 users in SCA2 and SCA3 patients, though not
statistically significant (P50.08 in SCA2 and P5 0.08
in SCA3). Only 8 SCA patients took both CoQ10 and
statins (2 SCA1, 3 SCA3, and 3 SCA6), and 19 SCA
patients took both CoQ10 and vitamin E (4 SCA1, 3
SCA2, 9 SCA3, and 3 SCA6). The sample size was too
small to investigate their interactions.
Discussion
We found that CoQ10 exposure was associated with
better outcomes indexed by SARA scores and UHDRS-
TABLE 1. Clinical features of 319 participants in the CRC-SCA at enrollment
SCA1 SCA2 SCA3 SCA6
Demographic feature
Sample size, n 53 69 129 68
Mean age, y (SD) 50.3 (13.0) 50.9 (13.5) 51.4 (12.3) 65.5 (10.8)
Sex, male/female 24/29 29/40 62/67 30/38
White race, % 90.6 73.9 54.2 91.2
Mean age of onset (SD) 40.2 (11.7) 36.4 (11.9) N5 68 38.9 (11.9) N5 127 52.3 (10.4)
Mean disease duration (SD) 8.8 (6.9) 13.6 (8.3) N5 68 11.5 (7.8) N5 128 11.7 (10.5)
Median repeats (range) 46 (37-59) N5 52 39 (23-49) N5 64 71 (60-79) N5 119 22 (22-27) N5 65
Functional state
SARA score (SD) 14.4 (8.2) 17.1 (7.4) 15.1 (8.9) N5 128 14.1 (7.4)
UHDRS-IV score (SD) 18.7 (6.3) 18.2 (6.3) N5 68 17.2 (6.9) 18.6 (5.8)
PHQ-9 score (SD) 6.1 (6.7) N5 49 5.3 (5.4) N5 64 7.3 (5.8) N5 123 6.5 (6.0) N5 64
Medication use, n (%)
Coenzyme Q10 14 (26.4) 9 (13.0) 31 (24.0) 20 (29.4)
Statin 8 (15.1) 7 (10.1) 15 (11.6) 13 (19.1)
Vitamin E 6 (11.3) 9 (13.0) 14 (10.9) 11 (16.2)
Riluzole 3 (5.7) 1 (1.4) 9 (7.0) 2 (2.9)
Varenicline 1 (1.9) 0 (0) 4 (3.1) 2 (2.9)
Sd, standard deviation.
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IV in SCA1 and 3 at baseline or cross-sectionally,
although none of these drugs modify the disease pro-
gression within the 2-year observation or longitudi-
nally. The dose-dependent effect of CoQ10 on SARA
scores was found in SCA3, but not significant in SCA1,
2, and 6. A larger sample size for SCA1, 2, and 6 is
warranted to clarify the difference.
The associations between CoQ10 exposure and clin-
ical outcomes in SCA1 and 3 appeared to be consist-
ent, but required cautious interpretation. CoQ10 was
in a trend of being associated with lower SARA scores
in SCA2 if not statistically significant (P50.11).
Because the percentage of patients exposed to CoQ10
in SCA2 was much lower than that in SCA1 or 3
(CoQ10 exposure: SCA1, 26.4%; SCA2, 13.0%;
SCA3, 24.0%), the CoQ10 effect may be noted if we
have more SCA2 participants taking CoQ10 included
in our analyses. However, the CoQ10 benefit we
observed could be the result of several reasons. Those
CoQ10 nonusers may have been exposed to CoQ10
earlier, but discontinued because of adverse effect or
no effect, for which we do not know. Patients who
have severe comorbid conditions requiring medical
intervention may be less likely given CoQ10 for
ataxia. All the above would make CoQ10 users look
healthier at baseline.
There is growing evidence that CoQ10 could be bene-
ficial in SCAs. CoQ10 is a cofactor of the mitochondrial
respiratory chain and plays an important role in main-
taining adequate mitochondrial function, whereas mito-
chondrial dysfunction is the common theme of neuronal
death in SCAs.11,12 Pathological polyglutamine expan-
sions in SCAs can form aggregates in neurons, which
activates caspase-8 and leads to mitochondrial apoptotic
neuronal death by up-regulating Bax and down-
regulating Bcl-xL.5-8,27 Mitochondrial complex I gene
polymorphism (10398G) is associated with early disease
onset of SCA2.28 Taken together, it is plausible that
CoQ10 can enhance mitochondrial function and pro-
vide clinical benefit to patients with polyglutamine-
related SCAs.
CoQ10 exposure was associated with both objective
(SARA) and subjective (UHDRS-IV) assessments at
baseline, but did not modify SCA disease progression
in our longitudinal analyses. There was no apparent
difference in baseline features, such as age of onset
FIG. 1. Baseline SARA scores of patients taking different daily dose of CoQ10 in all SCAs (A) or each SCA subtype (B–E). Box represents the first to
the third quartile and whiskers show the minimum and maximum values (A–E).
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and CAG repeat, between CoQ10 users and nonusers,
suggesting that the associations noted in our analyses
were not likely attributed to any genetic or inherited
difference. CoQ10 may require a longer period of
exposure to show clinical benefit in SCA1, 2, and 3.
Another possibility is that CoQ10 only brings sympto-
matic relief and therefore the rate of disease progres-
sion is not modified by CoQ10 exposure. A future
clinical trial is warranted to confirm the benefit of
CoQ10 in SCA.
The study has several unique features. First, SCA is
a rare disease and the CRC-SCA established a rela-
tively large cohort of SCA1, 2, 3, and 6 with informa-
tion collected in a standardized way, allowing us to
observe the clinical course of a rare disease with
respect to different drug exposures at a population
level. This is the only study, to our knowledge, to
look at the medication exposures and disease progres-
sion in a well-characterized cohort of SCAs. Second,
in addition to SARA, the study also included UHDRS-
IV, PHQ-9, and other indicators to follow disease pro-
gression so that not only motor symptoms, but also
other aspects of functional status can be comprehen-
sively assessed in SCAs. Third, most of our partici-
pants have information on CAG repeat number,
which is considered the major determinant for disease
onset and progression in SCAs.2,24 After adjusting for
the pathological CAG repeat number, the effect of
drug exposure can be examined in a less-biased way.
The study has many limitations. Although the com-
parison between CoQ10 users and nonusers was
made, many confounders, such as indication for
TABLE 2. Effects of CoQ10, statin, and vitamin E on
SARA scores in GEE models
Regression Coefficient in GEE Models
of SARA Scores
SCA 1 SCA 2 SCA 3 SCA 6
CoQ10 model
CoQ10 25.90a 23.20 25.54a 21.17
Time 0.15a 0.07 0.05 0.09
CoQ10 3 time 20.05 20.06 20.01 20.05
Statin model
Statin 21.29 21.08 21.26 4.50
Time 0.12a 0.08 0.06 0.07
Statin 3 time 0.04 20.09 20.07 0.05
Vitamin E model
Vitamin E 23.09 21.45 24.25 20.22
Time 0.12a 0.05 0.05 0.06
Vitamin E 3 Time 0.08 0.11 20.001 0.13
Entries are regression coefficients in the GEE models with the time-varying
SARA scores as the outcome of interest and age (year), sex (male/female),
pathological CAG repeat number (N), time (month), concurrent medication
(Y/N), and its interaction with time as predictors (coefficients of age, sex,
and CAG repeat are not shown in the table). The regression coefficients
can be interpreted as the change of SARA score per unit change of the
predictor variables.
aP< 0.01 or the rate of change is significantly different from zero.
TABLE 3. Effects of CoQ10, statin, and vitamin E on
UHDRS-IV scores in GEE models
Regression Coefficient in GEE Models
of UHDRS-IV Scores
SCA 1 SCA 2 SCA 3 SCA 6
CoQ10 model
CoQ10 4.85a 2.59 3.65a 1.87
Time 20.03 20.05 20.10a 20.08a
CoQ10 3 time 20.07 0.01 0.02 0.05
Statin model
Statin 3.30 2.92 1.11 23.33
Time 20.05 20.03 20.10a 20.08a
Statin 3 time 0.03 20.09 20.01 0.06
Vitamin E model
Vitamin E 3.44 20.10 2.52 0.88
Time 20.03 20.04 20.10a 20.05
Vitamin E 3 time 20.17 20.09 0.04 20.09
Entries are regression coefficients in the GEE models with the time-varying
UHDRS-IV scores as the outcome of interest and age (year), sex (male/
female), pathological CAG repeat number (N), time (month), concurrent
medication (Y/N), and its interaction with time as predictors (coefficients of
age, sex, and CAG repeat are not shown in the table). The regression coef-
ficients can be interpreted as the change of UHDRS-IV score per unit
change of the predictor variables.
aP<0.01.
TABLE 4. Clinical features of participants with and without coenzyme Q10 exposure
SCA1 SCA2 SCA3 SCA6
CoQ10 exposure Yes No Yes No Yes No Yes No
Sample size, n 14 39 9 60 31 98 20 48
Mean age, years 50.06 9.4 50.46 14.2 51.76 11.6 50.86 13.8 52.36 11.2 51.16 12.6 65.96 9.7 65.36 11.3
Male, % 28.6 51.3 33.3 43.3 58.1 44.9 40 45.8
White race, % 100 87.2 77.8 73.3 71 49 95 89.6
Age at onset, years 40.56 12.1 40.16 11.7 41.36 13.1 35.66 11.7 41.76 10.9 386 12.1 52.96 10.6 52.16 10.5
Disease duration, years 8.16 9.0 9.16 6.2 9.16 4.7 14.36 8.6 9.36 6.5 12.26 8.1 11.66 11.5 11.76 10.1
CAG repeats 45.96 2.8 46.26 4.9 38.86 2.2 39.76 3.8 71.26 3.5 70.66 4.2 22.46 0.7 22.46 1.0
Baseline SARA 9.26 5.8 16.26 8.2 13.76 5.7 17.66 7.5 12.56 8.3 16.06 9.0 13.76 8.5 14.26 7.0
Concomitant drugs, n 5.46 4.6 3.96 3.2 4.16 2.7 4.36 3.6 6.16 3.5 5.26 4.2 6.86 4.0 4.96 4.4
Mean6 standard deviation is reported.
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CoQ10, physician preference for prescribing CoQ10,
and patient motivation of using antioxidants,
remained unknown to us. Second, this 2-year follow-
up study may not be long enough to examine disease-
modifying effects of certain drugs. The average length
of exposure to CoQ10 before study enrollment among
CoQ10 users in our cohorts is approximately 3 years.
Therefore, the association between medication use and
disease progression may change if the CRC-SCA study
can be extended further. Many candidate medications
were included in the study, but not similarly distrib-
uted; CoQ10 was the most frequently used one, fol-
lowed by statins, whereas other drugs were rarely
given. We are not certain whether the significant drug
effects found in the study were simply the result of
higher statistical power. Nevertheless, the cohort size
and follow-up time of CRC-SCA study could be the
best possible data we have at the national level thus
far; the potential benefit of drug exposure deserves
attention given that there is no effectively disease-
modifying treatment for SCAs.
In sum, we found that CoQ10 exposure may be associ-
ated with better clinical status in SCA1 and 3. These
associations existed only at baseline, but did not replicate
during the 2-year observation. Given the disease rarity
and relentless progression, a clinical trial may more rigor-
ously determine the effect of CoQ10 in SCAs.
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